Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Tvardi Therapeutics (TVRD) Net Margin (2016 - 2025)

Tvardi Therapeutics' Net Margin history spans 13 years, with the latest figure at 92.88% for Q1 2025.

  • On a quarterly basis, Net Margin rose 129663.0% to 92.88% in Q1 2025 year-over-year; TTM through Mar 2025 was 337.39%, a 39180.0% increase, with the full-year FY2024 number at 992.95%, down 42774.0% from a year prior.
  • Net Margin hit 92.88% in Q1 2025 for Tvardi Therapeutics, up from 733.33% in the prior quarter.
  • Over the last five years, Net Margin for TVRD hit a ceiling of 5.0% in Q3 2021 and a floor of 4066.02% in Q4 2021.
  • Historically, Net Margin has averaged 799.21% across 5 years, with a median of 588.28% in 2022.
  • Biggest five-year swings in Net Margin: plummeted -413676bps in 2021 and later soared 310597bps in 2022.
  • Tracing TVRD's Net Margin over 5 years: stood at 4066.02% in 2021, then skyrocketed by 76bps to 960.04% in 2022, then dropped by -13bps to 1085.45% in 2023, then surged by 32bps to 733.33% in 2024, then skyrocketed by 87bps to 92.88% in 2025.
  • Business Quant data shows Net Margin for TVRD at 92.88% in Q1 2025, 733.33% in Q4 2024, and 215.69% in Q3 2024.